Wound Healing News and Research

RSS

Nuvo Research announces new licensing agreement for Oxoferin

Nuvo Research Inc., a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced a new licensing agreement for Oxoferin(TM), its topical wound healing agent, and additional details of the funding assistance to be provided by the Development Bank of Saxony for the development of WF10.

12 Nov 2009

Positive results from Puricore's Vashe Wound Therapy efficacy trial

PuriCore, the life sciences company focused on developing and commercializing proprietary solutions that safely, effectively, and naturally kill infectious pathogens, today announced results of a randomized clinical trial showing the potential effectiveness of its Vashe Wound Therapy in the post-operative care of split-thickness skin grafts for burn injuries.

11 Nov 2009

Gonorrhea medication may help fight cancer

Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease. The newest surprise discovered by researchers at the Johns Hopkins University School of Medicine is a gonorrhea medication that might help battle cancer.

6 Nov 2009

IBN iCare to develop cutting-edge nanomaterials for ocular therapy

Marking a significant bench to bedside research milestone in Singapore, the Institute of Bioengineering and Nanotechnology (IBN), the world's first bioengineering and nanotechnology research institute, and the National University Hospital (NUH) launched the IBN iCare and the NUH Eye Centre @ Biopolis at an official opening ceremony officiated by the Senior Minister of State for Trade and Industry and Education, S. Iswaran, at the Biopolis on Nov. 3, 2009.

4 Nov 2009

Arrowhead Research updates its shareholders

Arrowhead Research Corporation’s (NASDAQ: ARWR) President and Chief Executive Officer today issued the following letter to the Company’s shareholders.

3 Nov 2009

Cardium Therapeutics to seek FDA marketing clearance for ExcellagenXL

Cardium Therapeutics today announced plans to submit a 510(k) premarket notification with the U.S. Food and Drug Administration (FDA) seeking marketing clearance of its ExcellagenXL(TM) product candidate.

3 Nov 2009

UT Southwestern ophthalmologist receives 2009 Castroviejo Medal

Dr. H. Dwight Cavanagh, vice chairman of ophthalmology at UT Southwestern Medical Center, has been named the 2009 recipient of the prestigious Castroviejo Medal, one of the top ophthalmology prizes in the world.

30 Oct 2009

Comparative study of chronic wound treatment completed

The comparative study of chronic wound treatment at the Hospital Civil of Cd. Victoria, Tamaulipas, Mexico, was concluded successfully. Due to the significantly superior therapeutic success the Ministry of Health ordered the control to be abandoned and moved to Hemospray treatment for ethical reasons.

30 Oct 2009

Prospera Technologies presents data on its Gauze vs. Foam based NPWT research

Prospera Technologies announced today that, at the Clinical Symposium on Advances in Skin & Wound Care in San Antonio, Texas, Oct 22-25, 2009, Malin Malmsjo MD., Ph.D. of Lund University in Lund, Sweden, presented significant new research comparing the differences and quality of granulation tissue in foam versus gauze based NPWT.

29 Oct 2009

Helix BioMedix' SmartPeptides technology products demonstrate improvement in skin texture

Helix BioMedix, Inc., a developer of bioactive peptides, today announced the completion of a series of three clinical studies investigating the safety and efficacy of a serum, eye cream and moisturizer, each containing the Company’s SmartPeptides™ technology, including the newly developed Heptapeptide-7. These studies demonstrate improvement in skin texture and appearance as well as the decrease in fine lines and wrinkles with Striking™ Skin Care formulations.

28 Oct 2009

Probiotic therapy can be effective for treating intestinal disorders

The probiotic, Bacillus polyfermenticus, can help mice recover from colitis, a new study has found. Mice treated with B. polyfermenticus during the non-inflammatory period of the disease had reduced rectal bleeding, their tissues were less inflamed and they gained more weight than mice that did not receive the treatment.

26 Oct 2009

ULURU presents clinical posters; highlights efficacy of Altrazeal dressing for wound care

ULURU Inc. (NYSE Alternext: ULU) today announced that Gregory Bohn, M.D., FACS, Medical Director, Trinity Wound Care and Hyperbaric Medicine, Bettendorf, Iowa, has presented nine clinical posters at the 24th Annual "Clinical Symposium on Advances in Skin and Wound Care" being held in San Antonio, Texas.

24 Oct 2009

AGH Researchers to study the impact of biofilm infections on the success of orthopaedic procedures

Researchers from Allegheny General Hospital's (AGH) Department of Orthopaedic Surgery and Center for Genomic Sciences have launched dual groundbreaking studies that may help determine the cause of two common, hard-to-treat problems experienced by patients who undergo orthopedic surgery: a joint replacement that becomes infected and a bone fracture that will not heal properly.

24 Oct 2009

Guidance for Quick-Med Technologies’ NIMBUS barrier gauze wound dressings issued

Quick-Med Technologies, Inc. announced today that the Food and Drug Administration has issued Guidance to support the classification of the Company’s NIMBUS® barrier gauze wound dressings as Class II medical devices.

23 Oct 2009

Update from SemBioSys Genetics regarding Botaneco Specialty Ingredients

SemBioSys Genetics Inc. today announced that Advitech Inc. ("Advitech") has entered into a definitive agreement to acquire all of the issued and outstanding shares of Botaneco Specialty Ingredients Inc. ("Botaneco") held by SemBioSys and Avrio Ventures Limited Partnership ("Avrio").

21 Oct 2009

New 3D scaffolding technology may help grow skin and blood vessels in labs

Scientists are developing new scaffolding technology which could be used to grow tissues such as skin, nerves and cartilage using 3D spaghetti-like structures. Their research is highlighted in the latest issue of Business, the quarterly highlights magazine of the Biotechnology and Biological Sciences Research Council (BBSRC).

19 Oct 2009

Cardium Therapeutics reports positive findings from Excellarate Phase 1/2 clinical study

Cardium Therapeutics today announced the publication of positive findings from the open label multi-center Phase 1/2 clinical study of Excellarate(TM) (GAM501, Ad5PDGF-B / 2.6% collagen), its product candidate for the potential treatment of non-healing diabetic foot ulcers.

19 Oct 2009

Positive data from Cardium Therapeutics' Matrix Phase 2b Excellarate trial

Cardium Therapeutics today reported positive data from its Matrix Phase 2b clinical trial of Excellarate(TM) for the potential treatment of patients with chronic non-healing diabetic foot ulcers based on the Company's Gene Activated Matrix (GAM) technology platform.

15 Oct 2009

Systagenix Wound Management forms new global Medical Advisory Board

Systagenix Wound Management has announced the formation of a new global Medical Advisory Board, consisting of a group of multi-disciplinary and highly respected wound care clinicians and practitioners from North America and Europe, which will be led by Systagenix's newly appointed Medical Director, Dr Robert Snyder.

13 Oct 2009

SANUWAVE presents findings on extracorporeal shock wave stimulation of osteoprogenitor cells

SANUWAVE, Inc., an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, reported that scientific findings titled “Extracorporeal Shock Wave Stimulation of Osteoprogenitor Cells” were presented at the 2009 International Bone-Tissue-Engineering Congress (“Bone-Tec”) in Hannover, Germany, which was held October 9-11, 2009.

13 Oct 2009